Published in Blood on November 01, 1998
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol (2012) 3.52
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature (2011) 3.10
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J (2003) 2.72
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 2.56
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood (2005) 2.54
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem (2009) 2.06
New strategies in the treatment of multiple myeloma. Clin Cancer Res (2013) 2.05
Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry (2006) 1.96
Regulation of the different chromatin states of autosomes and X chromosomes in the germ line of C. elegans. Science (2002) 1.84
The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol (2015) 1.82
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood (2005) 1.81
Cell of origin strongly influences genetic selection in a mouse model of T-ALL. Blood (2011) 1.78
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77
NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am J Hum Genet (2002) 1.65
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood (2007) 1.60
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer (2010) 1.56
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene (2007) 1.49
The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J Biol Chem (2010) 1.41
Genomics in multiple myeloma. Clin Cancer Res (2011) 1.34
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell (2012) 1.34
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov (2014) 1.27
MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res (2006) 1.27
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest (2012) 1.21
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica (2008) 1.20
Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res (2011) 1.16
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun (2015) 1.14
Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood (2005) 1.13
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer (2008) 1.12
The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood (2001) 1.12
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget (2015) 1.08
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia (2011) 1.08
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene (2012) 1.07
Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol Cell Biol (2009) 1.05
"Snorkeling" for missing players in cancer. J Clin Invest (2012) 1.05
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica (2011) 1.01
An ATM homologue from Arabidopsis thaliana: complete genomic organisation and expression analysis. Nucleic Acids Res (2000) 1.00
A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. Blood (2013) 1.00
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell (2016) 0.98
KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget (2015) 0.98
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J (2012) 0.97
Deletions involving genes WHSC1 and LETM1 may be necessary, but are not sufficient to cause Wolf-Hirschhorn Syndrome. Eur J Hum Genet (2013) 0.97
Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs (2009) 0.96
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica (2015) 0.96
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol (2013) 0.96
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Radiation leukemia virus common integration at the Kis2 locus: simultaneous overexpression of a novel noncoding RNA and of the proximal Phf6 gene. J Virol (2005) 0.95
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene (2012) 0.95
Nizp1, a novel multitype zinc finger protein that interacts with the NSD1 histone lysine methyltransferase through a unique C2HR motif. Mol Cell Biol (2004) 0.93
Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene (2010) 0.93
Genetics of multiple myeloma: another heterogeneity level? Blood (2015) 0.91
Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol (2000) 0.89
Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS One (2011) 0.87
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes. Genes Chromosomes Cancer (2014) 0.86
Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. J Hematol Oncol (2010) 0.86
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol (2011) 0.86
Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am (2007) 0.86
A nucleosome surface formed by histone H4, H2A, and H3 residues is needed for proper histone H3 Lys36 methylation, histone acetylation, and repression of cryptic transcription. J Biol Chem (2010) 0.86
Mechanism of FGF receptor dimerization and activation. Nat Commun (2016) 0.86
In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L. BMC Struct Biol (2014) 0.86
MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer J (2013) 0.85
Molecular aspects of multiple myeloma. Mol Pathol (2002) 0.85
Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts. J Mol Diagn (2007) 0.85
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget (2016) 0.85
Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol (2001) 0.84
Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. Leukemia (2010) 0.84
Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood (2013) 0.83
Molecular pathogenesis of multiple myeloma. Int J Clin Oncol (2015) 0.83
New frontiers in the treatment of multiple myeloma. ScientificWorldJournal (2006) 0.83
Epigenetic modifications in pediatric acute lymphoblastic leukemia. Front Pediatr (2014) 0.82
Perspectives and future directions for epigenetics in hematology. Blood (2013) 0.82
Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen (2009) 0.82
Critical signal transduction pathways in CLL. Adv Exp Med Biol (2013) 0.81
Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. Oncotarget (2013) 0.81
MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication. Cell Cycle (2016) 0.81
Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol (2016) 0.81
Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J Clin Invest (2016) 0.80
MMSET: role and therapeutic opportunities in multiple myeloma. Biomed Res Int (2014) 0.80
MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib. Leukemia (2015) 0.80
Genetic markers used for risk stratification in multiple myeloma. Genet Res Int (2011) 0.79
Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. Curr Opin Oncol (2015) 0.79
Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36. Proc Natl Acad Sci U S A (2016) 0.78
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther (2012) 0.78
MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis. Haematologica (2015) 0.77
Epigenetics of hematopoiesis and hematological malignancies. Genes Dev (2016) 0.77
A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochim Biophys Acta (2016) 0.77
Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3. Ther Clin Risk Manag (2005) 0.77
[Molecular pathology of plasma cell neoplasms]. Pathologe (2010) 0.77
Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles. Biochim Biophys Acta (2016) 0.76
Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody. Dis Model Mech (2016) 0.76
Everybody's welcome: The big tent approach to epigenetic drug discovery. Drug Discov Today Ther Strateg (2011) 0.76
A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin. J Biol Chem (2016) 0.76
NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation. Sci Rep (2016) 0.75
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 14.24
Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci U S A (1977) 13.87
The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A (2000) 9.67
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
A systematic, high-resolution linkage of the cytogenetic and physical maps of the human genome. Nat Genet (2000) 4.78
Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A (1999) 4.49
Differential expression of c-myb mRNA in murine B lymphomas by a block to transcription elongation. Science (1987) 3.49
Origin of the human L1 elements: proposed progenitor genes deduced from a consensus DNA sequence. Genomics (1987) 3.21
Somatic cell hybridization of mouse myeloma cells. Cell (1976) 3.17
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 3.11
Isolation and characterization of myosin and two myosin fragments from human blood platelets. Proc Natl Acad Sci U S A (1971) 3.09
Complete amino-acid sequence of actin of rabbit skeletal muscle. Proc Natl Acad Sci U S A (1973) 2.96
Isolation and characterization of a major tandem repeat family from the human X chromosome. Nucleic Acids Res (1983) 2.94
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A (2000) 2.81
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Chromosome translocations in multiple myeloma. Oncogene (2001) 2.61
Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature (1986) 2.57
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood (2001) 2.48
Isolation and characterization of cloned human DNA fragments carrying reiterated sequences common to both autosomes and the X chromosome. Nucleic Acids Res (1981) 2.41
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood (1998) 2.36
SV40 recombinants carrying rabbit beta-globin gene coding sequences. Cell (1979) 2.35
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood (1996) 2.21
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A (1996) 2.15
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia (2011) 2.12
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12
Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med (1998) 2.08
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Murine myb protooncogene mRNA: cDNA sequence and evidence for 5' heterogeneity. Proc Natl Acad Sci U S A (1986) 2.05
Human Y-chromosome-specific reiterated DNA. Science (1976) 2.02
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97
The introduction of radioisotopes into RNA by methylation in vitro. Biochim Biophys Acta (1967) 1.84
Statistical analysis of MPSS measurements: application to the study of LPS-activated macrophage gene expression. Proc Natl Acad Sci U S A (2005) 1.84
An Asian-Native American paternal lineage identified by RPS4Y resequencing and by microsatellite haplotyping. Ann Hum Genet (1999) 1.78
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Formation of an intrachain disulfide bond on nascent immunoglobulin light chains. J Biol Chem (1979) 1.76
A rapidly spinning supermassive black hole at the centre of NGC 1365. Nature (2013) 1.73
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia (2006) 1.71
Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol (2001) 1.71
Prenatal diagnosis of sickle cell anemia by restriction and endonuclease analysis: HindIII polymorphisms in gamma-globin genes extend test applicability. Proc Natl Acad Sci U S A (1980) 1.71
Structural studies on rabbit skeletal actin. I. Isolation and characterization of the peptides produced by cyanogen bromide cleavage. Biochemistry (1970) 1.69
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med (1995) 1.63
Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood (1992) 1.62
Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol (2000) 1.59
Use of formamide in nucleic acid reassociation. Biochemistry (1972) 1.56
Synthesis of a carboxyl-terminal (constant region) fragment of the immunoglobulin light chain by a mouse myeloma cell line. J Mol Biol (1974) 1.54
Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis (1992) 1.52
Formation of intermolecular disulfide bonds on nascent immunoglobulin polypeptides. J Biol Chem (1979) 1.49
Cloned MPC 11 myeloma cells express two kappa genes: a gene for a complete light chain and a gene for a constant region polypeptide. Cell (1977) 1.44
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy. Leukemia (2008) 1.43
Fecal Isolation of Corynebacterium equi from a Foal with Chronic Diarrhea. Can Vet J (1984) 1.43
Clinical use of a concomitant boost technique using a gypsum compensator. Int J Radiat Oncol Biol Phys (1994) 1.39
Recognition and destruction of Bacillus Calmette-Guerin-infected human monocytes. J Exp Med (1993) 1.39
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia (2006) 1.39
A familial centric chromosome fragment. Cytogenetics (1965) 1.38
Induction of light chain expression in a pre-B cell line by fusion to myeloma cells. Nature (1981) 1.35
Is semen cryopreservation helpful in testicular cancer? Urology (1980) 1.32
Evidence for increased prevalence of SRY mutations in XY females with complete rather than partial gonadal dysgenesis. Am J Hum Genet (1992) 1.30
Addition of glucosamine and mannose to nascent immunoglobulin heavy chains. Biochemistry (1977) 1.26
Circannual rhythm in human sperm count revealed by serially independent sampling. Fertil Steril (1982) 1.25
Characterization and evolution of a single-copy sequence from the human Y chromosome. Mol Cell Biol (1985) 1.25
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia (2008) 1.24
Population heterogeneity of the Hpa I restriction site associated with the beta globin gene: implications for prenatal diagnosis. Am J Hum Genet (1981) 1.22
Molecular aspects of chromatin elimination in Ascaris lumbricoides. Dev Biol (1972) 1.22
Characterization of light chain and light chain constant region fragment mRNAs in MPC 11 mouse myeloma cells and variants. Cell (1975) 1.22
Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood (2000) 1.21
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia (2013) 1.21
Functional analysis of c-Myb protein in T-lymphocytic cell lines shows that it trans-activates the c-myc promoter. Mol Cell Biol (1990) 1.20
A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A (1997) 1.20
A murine cDNA encodes a pan-epithelial glycoprotein that is also expressed on plasma cells. J Immunol (1992) 1.19
Differentiation of mouse erythroleukemia cells is blocked by late up-regulation of a c-myb transgene. Mol Cell Biol (1990) 1.19
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia (2007) 1.18
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood (2001) 1.17
Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell (1999) 1.16
Template specificity of isolated chromatin. Biochemistry (1969) 1.16
Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia (2002) 1.15
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood (2001) 1.15
Co-translational modification of nascent immunoglobulin heavy and light chains. J Supramol Struct (1979) 1.14
Disruption of the Saccharomyces cerevisiae FAT1 gene decreases very long-chain fatty acyl-CoA synthetase activity and elevates intracellular very long-chain fatty acid concentrations. J Biol Chem (1998) 1.14
A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy. Clin Nephrol (2006) 1.14
Prenatal diagnosis of hemoglobinopathies by restriction endonuclease analysis: pregnancies at risk for sickle cell anemia and S--O Arab disease. Johns Hopkins Med J (1979) 1.12
Immune response to the src gene product in mice bearing tumors induced by injection of avian sarcoma virus-transformed mouse cells. J Virol (1979) 1.11
Co-operative induction of pro-inflammatory signaling by Toll-like receptors. J Endotoxin Res (2000) 1.11
Application for PCR technology to subtractive cDNA cloning: identification of genes expressed specifically in murine plasmacytoma cells. Nucleic Acids Res (1990) 1.10
Temporal relationship of translation and glycosylation of immunoglobulin heavy and light chains. Biochemistry (1978) 1.10
NK cell natural cytotoxicity and IFN-gamma production are not always coordinately regulated: engagement of DX9 KIR+ NK cells by HLA-B7 variants and target cells. J Immunol (1998) 1.10